Pliant Therapeutics, Inc.

Pliant Therapeutics, Inc.

0.62
EUR
0.00
(0.00%)
-1.31EPS
62.23MMarket Cap
Mar 17Next Earn

Total Valuation

EUR

As of June 30, 2026, Pliant Therapeutics, Inc. carries a market capitalization of 62.23M, placing it among publicly traded companies globally. Its enterprise value stands at -51.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap62.23M
Enterprise Value-51.00M

Important Dates

Pliant Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 17, 2027.

Earnings Date3/17/2027

Share Statistics

As of June 30, 2026, Pliant Therapeutics, Inc. has 61.92M shares outstanding.

Shares Outstanding61.92M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio0.48
P/TBV Ratio0.48
P/FCF Ratio-1.00
P/OCF Ratio-1.00

Financial Position

As of June 30, 2026, Pliant Therapeutics, Inc. maintains a current ratio of 9.90, meaning it holds 9.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.56, indicating elevated leverage, while an interest coverage ratio of -101.12 demonstrates limited ability to service its debt obligations.

Current Ratio9.90
Quick Ratio9.64
Debt / Equity19.56
Debt / EBITDA-0.30
Interest Coverage-101.12

Financial Efficiency

Over the twelve months ended June 30, 2026, Pliant Therapeutics, Inc. posted a negative return on equity (ROE) of -50.29, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -37.69, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 79.50, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-50.29
Return on Assets (ROA)-37.69
Employee Count79.50

Stock Price Statistics

EUR

As of the close on November 17, 2026, Pliant Therapeutics, Inc.'s stock has declined approximately 56.23% over the past 52 weeks. The 50-day moving average sits at 0.85, while the 200-day moving average is 0.98.

52-Week Price Change-56.23%
50-Day Moving Average0.85
200-Day Moving Average0.98

Income Statement

EUR

Over the twelve months ended June 30, 2026, Pliant Therapeutics, Inc. generated - - in revenue and converted that into -80.78M in net income, yielding earnings per share of -1.31. EBITDA reached -84.17M, while operating income came in at -85.32M.

Operating Income-85.32M
Pretax Income-80.78M
Net Income-80.78M
EBITDA-84.17M
EBIT-85.32M
Earnings Per Share (EPS)-1.31

Balance Sheet

EUR

As of June 30, 2026, Pliant Therapeutics, Inc. holds 138.39M in cash and equivalents against 25.16M in total debt, resulting in a net debt position of -21.78M. Total book value stands at 128.60M, with working capital of 128.37M providing operational flexibility.

Cash & Cash Equivalents138.39M
Total Debt25.16M
Net Debt-21.78M
Equity (Book Value)128.60M
Book Value Per Share2.08
Working Capital128.37M

Cash Flow

EUR

Pliant Therapeutics, Inc. produced -62.05M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -62.05M - equivalent to -1.01 per share.

Operating Cash Flow-62.05M
Free Cash Flow-62.05M
FCF Per Share-1.01

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -100.16: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 45.18, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Pliant Therapeutics, Inc. shareholders.

Shareholder Yield45.18
FCF Yield-100.16

Scores

As of June 30, 2026, Pliant Therapeutics, Inc. has an Altman Z-Score of -6.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-6.42